Seqster, a San Diego-based healthcare company that aims to build comprehensive patient records, announced Tuesday that it is partnering with the National Pancreas Foundation (NPF) to create the nation’s largest database of dynamic pancreatic patient disease. The database can drive cutting-edge research faster than traditional methods.
Seqster’s technology will power the registry, connecting patient data from wearable/remote monitoring devices, genomic DNA tests and EHRs in real time. The company’s platform collects data for patients from a range of sources, enabling more comprehensive and cohesive care.
The registry is designed to benefit both patients and researchers. First, patients with pancreatic cancer and other conditions such as pancreatitis will have real-time access to their comprehensive longitudinal health records, as will their providers. In particular, the database can serve as a comprehensive tool to collect health information from a variety of different devices and multiple providers, enabling more cohesive care.
“Now is the perfect time to create a dynamic patient registry, as Seqster has real-time real-world data (RWD) collection technology that can provide new insights and accelerate drug discovery. Longitudinal health records are extremely valuable for both patients and research,” Seqster’s joint Founder and CEO Ardy Arianpour said in an email.
Pancreatic cancer is the third most deadly cancer in the United States, accounting for 3 percent of cancer cases, according to a press release announcing the collaboration. Registries could change the pace of research moving forward.
Jane Holt, co-founder of NPF, said: “The new NPF registry powered by Seqster technology is a true leadership initiative that leverages an industry-leading patient-centric platform and allows our institutional partners to analyze, visualize and query Leading data.” in a press release. “This will lead to greater understanding of new treatments, predictive biomarkers, and significantly improved patient outcomes.”
Arianpour also stressed that the patient registry will protect patient privacy.
“We designed our software and our infrastructure from the ground up with privacy and security first,” Arianpur said. “Our servers are hosted on a fully HIPPA compliant platform that is certified to the most stringent healthcare industry security standards, including HITRUST. Our technology is more secure than most hospital system EHRs, which typically use comparable Outdated encryption to store data.”
While this will advance research in pancreatic diseases and accelerate drug development, Seqster has other partnerships aimed at accelerating clinical trials.Takeda, a Japanese company that is an investor in Seqster, also owns Cooperation agreement It uses Seqster’s platform to engage patients and enroll them in clinical trials.
Photo: Mikdan, Getty Images
